Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.31 Insider Own38.32% Shs Outstand218.05M Perf Week2.75%
Market Cap742.03M Forward P/E- EPS next Y-0.43 Insider Trans0.18% Shs Float153.07M Perf Month-9.39%
Income-68.87M PEG- EPS next Q-0.06 Inst Own48.15% Short Float4.00% Perf Quarter36.53%
Sales0.00M P/S- EPS this Y20.45% Inst Trans-7.65% Short Ratio3.64 Perf Half Y124.81%
Book/sh2.71 P/B1.10 EPS next Y-52.91% ROA-10.84% Short Interest6.12M Perf Year67.98%
Cash/sh2.41 P/C1.24 EPS next 5Y- ROE-11.15% 52W Range0.95 - 4.16 Perf YTD98.01%
Dividend Est.- P/FCF- EPS past 5Y- ROI-11.56% 52W High-28.12% Beta1.41
Dividend TTM- Quick Ratio38.58 Sales past 5Y0.00% Gross Margin- 52W Low214.74% ATR (14)0.21
Dividend Ex-Date- Current Ratio38.58 EPS Y/Y TTM34.50% Oper. Margin0.00% RSI (14)50.35 Volatility5.98% 7.13%
Employees51 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.60
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q32.02% Payout- Rel Volume0.50 Prev Close2.92
Sales Surprise- EPS Surprise23.66% Sales Q/Q- EarningsMay 14 AMC Avg Volume1.68M Price2.99
SMA20-1.64% SMA50-1.76% SMA20052.21% Trades Volume840,726 Change2.40%
Date Action Analyst Rating Change Price Target Change
Mar-27-24Upgrade Jefferies Hold → Buy $1.40 → $10
Mar-26-24Upgrade BTIG Research Neutral → Buy $5
Jan-06-23Downgrade Jefferies Buy → Hold $5 → $2
Aug-02-22Downgrade BTIG Research Buy → Neutral
Aug-02-22Downgrade BMO Capital Markets Outperform → Market Perform $8 → $2.50
May-04-22Initiated H.C. Wainwright Buy $14
Oct-15-21Resumed BTIG Research Buy $16
Apr-06-21Initiated RBC Capital Mkts Outperform $15
Mar-08-21Initiated Wedbush Outperform $20
Mar-08-21Initiated Jefferies Buy $20
Jun-02-24 01:13AM
Jun-01-24 08:10AM
May-29-24 04:05PM
May-14-24 10:54PM
04:05PM Loading…
Apr-24-24 10:01AM
Apr-10-24 04:01PM
Mar-28-24 08:00AM
Mar-25-24 07:00AM
Mar-14-24 04:05PM
Mar-08-24 12:00PM
Feb-29-24 04:01PM
Feb-27-24 03:30AM
04:10PM Loading…
Jan-08-24 04:10PM
Nov-13-23 04:05PM
Nov-02-23 06:04PM
Aug-03-23 04:10PM
Jul-13-23 09:45AM
Jun-01-23 04:05PM
May-16-23 06:23AM
May-04-23 04:05PM
Mar-21-23 05:10PM
Mar-18-23 06:48PM
Mar-15-23 04:05PM
Feb-17-23 05:05AM
Jan-17-23 08:19AM
04:05PM Loading…
Dec-19-22 04:05PM
Dec-07-22 05:03AM
Nov-03-22 04:05PM
Aug-11-22 10:01AM
Aug-10-22 08:45AM
Aug-04-22 04:05PM
Aug-01-22 04:00PM
Jul-27-22 12:00PM
Jul-18-22 07:00AM
Jun-27-22 08:52AM
May-23-22 11:36AM
May-09-22 04:05PM
Feb-28-22 04:05PM
Jan-21-22 10:21AM
Jan-20-22 08:43AM
Jan-14-22 12:31PM
Jan-10-22 07:00AM
Dec-17-21 08:00AM
Dec-15-21 07:00AM
Dec-13-21 10:33AM
Dec-08-21 07:00AM
Nov-19-21 08:24AM
Nov-10-21 04:05PM
Oct-25-21 09:12AM
Sep-20-21 04:14PM
Aug-12-21 04:05PM
Jul-06-21 10:20AM
Jun-01-21 07:00AM
May-26-21 07:00AM
May-21-21 04:34PM
May-17-21 05:00PM
May-11-21 05:51AM
Apr-17-21 09:36PM
Mar-11-21 05:15PM
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLICKENSTAFF KIM DDirectorJun 11 '24Buy2.90172,189500,089172,189Jun 13 04:33 PM
WELCH DANIEL GDirectorMay 24 '24Option Exercise1.68659,9471,111,633659,947May 29 04:38 PM